Skip to main content

Table 2 Main adverse events of any cause in 3 months

From: Sequential everolimus for angiomyolipoma associated with tuberous sclerosis complex: a prospective cohort study

Variables

Standard (n = 23)

Sequential (n = 30)

P value

All grade

Grade 3/4

All Grade

Grade 3/4

Total

23 (100)

6 (26)

29 (97)

9 (30)

0.780/0.690

Mouth ulceration

23 (100)

3 (13)

29 (97)

4 (13)

 

Hypertriglyceridemia

14 (61)

2 (9)

16 (53)

2 (7)

 

Hypercholesterolemia

14 (61)

2 (9)

17 (57)

2 (7)

 

Menstrual disorder

8 (44)

1 (4)

10 (42)

1 (4)

 

Urinary tract infection

8 (35)

0 (0)

8 (27)

1 (4)

 

Rash

5 (22)

1 (4)

7 (23)

1 (4)

 

Headache

5 (22)

1 (4)

6 (20)

0 (0)

 

Gastritis

5 (22)

0 (0)

6 (20)

1 (4)

 

Liver dysfunction

4 (17)

2 (9)

4 (13)

2 (7)

 

Fatigue

4 (17)

1 (4)

6 (20)

1 (4)

 

Non-infectious pneumonia

4 (17)

0 (0)

3 (10)

0 (0)

 

Anemia

3 (13)

0 (0)

5 (17)

1 (4)

 

Renal dysfunction

3 (13)

0 (0)

4 (13)

0 (0)

 

Epileptic seizure

2 (9)

0 (0)

1 (4)

0 (0)